<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table2" position="float"><object-id pub-id-type="doi">10.7554/eLife.45594.018</object-id><label>Table 2.</label><caption><title>Incidence rates of seroconversion and seroreversion per child year among children ages 0&#8211;11 years in Haiti, 1990&#8211;1999.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom"/><th colspan="3" valign="bottom">Seropositivity cutoff *</th><th colspan="3" valign="bottom">4-Fold change in IgG levels &#8224;</th><th valign="bottom"/><th valign="bottom"/></tr><tr><th valign="bottom">Pathogen</th><th valign="bottom">Child- years</th><th valign="bottom">Incident cases</th><th valign="bottom">Rate <break/>(95% CI)</th><th valign="bottom">Child- years</th><th valign="bottom">Incident cases</th><th valign="bottom">Rate <break/>(95% CI)</th><th valign="bottom">Ratio of cases</th><th valign="bottom">Ratio of rates</th></tr></thead><tbody><tr><td valign="bottom">Seroconversion/boosting</td><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">&#8195;<italic>Giardia</italic> VSP-3 or VSP-5</td><td valign="bottom">269.6</td><td valign="bottom">108</td><td valign="bottom">0.40 (0.34, 0.48)</td><td valign="bottom">277.2</td><td valign="bottom">120</td><td valign="bottom">0.43 (0.35, 0.54)</td><td valign="bottom">1.1</td><td valign="bottom">1.1</td></tr><tr><td valign="bottom">&#8195;<italic>Cryptosporidium</italic> Cp17 or Cp23</td><td valign="bottom">109.3</td><td valign="bottom">70</td><td valign="bottom">0.64 (0.54, 0.77)</td><td valign="bottom">241.0</td><td valign="bottom">204</td><td valign="bottom">0.85 (0.73, 0.97)</td><td valign="bottom">2.9</td><td valign="bottom">1.3</td></tr><tr><td valign="bottom">&#8195;<italic>E. histolytica</italic> LecA</td><td valign="bottom">283.7</td><td valign="bottom">97</td><td valign="bottom">0.34 (0.28, 0.42)</td><td valign="bottom">297.1</td><td valign="bottom">107</td><td valign="bottom">0.36 (0.29, 0.45)</td><td valign="bottom">1.1</td><td valign="bottom">1.1</td></tr><tr><td valign="bottom">&#8195;<italic>Salmonella</italic> LPS groups B or D</td><td valign="bottom">132.1</td><td valign="bottom">75</td><td valign="bottom">0.57 (0.47, 0.68)</td><td valign="bottom">226.8</td><td valign="bottom">149</td><td valign="bottom">0.66 (0.54, 0.80)</td><td valign="bottom">2.0</td><td valign="bottom">1.2</td></tr><tr><td valign="bottom">&#8195;ETEC LT B subunit</td><td valign="bottom">9.7</td><td valign="bottom">11</td><td valign="bottom">1.13 (0.75, 1.82)</td><td valign="bottom">32.1</td><td valign="bottom">32</td><td valign="bottom">1.00 (0.70, 1.45)</td><td valign="bottom">2.9</td><td valign="bottom">0.9</td></tr><tr><td valign="bottom">&#8195;Norovirus GI.4</td><td valign="bottom">213.0</td><td valign="bottom">80</td><td valign="bottom">0.38 (0.30, 0.47)</td><td valign="bottom">254.3</td><td valign="bottom">107</td><td valign="bottom">0.42 (0.34, 0.53)</td><td valign="bottom">1.3</td><td valign="bottom">1.1</td></tr><tr><td valign="bottom">&#8195;Norovirus GII.4.NO</td><td valign="bottom">105.8</td><td valign="bottom">67</td><td valign="bottom">0.63 (0.51, 0.80)</td><td valign="bottom">147.2</td><td valign="bottom">100</td><td valign="bottom">0.68 (0.54, 0.86)</td><td valign="bottom">1.5</td><td valign="bottom">1.1</td></tr><tr><td valign="bottom">Seroreversion/waning</td><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/><td valign="bottom"/></tr><tr><td valign="bottom">&#8195;<italic>Giardia</italic> VSP-3 or VSP-5</td><td valign="bottom">441.6</td><td valign="bottom">91</td><td valign="bottom">0.21 (0.17, 0.25)</td><td valign="bottom">290.9</td><td valign="bottom">127</td><td valign="bottom">0.44 (0.35, 0.54)</td><td valign="bottom">1.4</td><td valign="bottom">2.1</td></tr><tr><td valign="bottom">&#8195;<italic>Cryptosporidium</italic> Cp17 or Cp23</td><td valign="bottom">586.1</td><td valign="bottom">29</td><td valign="bottom">0.05 (0.03, 0.07)</td><td valign="bottom">273.5</td><td valign="bottom">171</td><td valign="bottom">0.63 (0.53, 0.74)</td><td valign="bottom">5.9</td><td valign="bottom">12.6</td></tr><tr><td valign="bottom">&#8195;<italic>E. histolytica</italic> LecA</td><td valign="bottom">395.2</td><td valign="bottom">43</td><td valign="bottom">0.11 (0.08, 0.15)</td><td valign="bottom">310.4</td><td valign="bottom">67</td><td valign="bottom">0.22 (0.16, 0.27)</td><td valign="bottom">1.6</td><td valign="bottom">2.0</td></tr><tr><td valign="bottom">&#8195;<italic>Salmonella</italic> LPS groups B or D</td><td valign="bottom">544.3</td><td valign="bottom">25</td><td valign="bottom">0.05 (0.03, 0.07)</td><td valign="bottom">344.5</td><td valign="bottom">89</td><td valign="bottom">0.26 (0.20, 0.32)</td><td valign="bottom">3.6</td><td valign="bottom">5.6</td></tr><tr><td valign="bottom">&#8195;ETEC LT B subunit</td><td valign="bottom">702.1</td><td valign="bottom">2</td><td valign="bottom">0.00 (0.00, 0.01)</td><td valign="bottom">649.7</td><td valign="bottom">22</td><td valign="bottom">0.03 (0.02, 0.05)</td><td valign="bottom">11.0</td><td valign="bottom">11.9</td></tr><tr><td valign="bottom">&#8195;Norovirus GI.4</td><td valign="bottom">464.9</td><td valign="bottom">28</td><td valign="bottom">0.06 (0.03, 0.09)</td><td valign="bottom">362.2</td><td valign="bottom">56</td><td valign="bottom">0.15 (0.11, 0.21)</td><td valign="bottom">2.0</td><td valign="bottom">2.6</td></tr><tr><td valign="bottom">&#8195;Norovirus GII.4.NO</td><td valign="bottom">574.3</td><td valign="bottom">19</td><td valign="bottom">0.03 (0.02, 0.05)</td><td valign="bottom">477.9</td><td valign="bottom">39</td><td valign="bottom">0.08 (0.06, 0.11)</td><td valign="bottom">2.1</td><td valign="bottom">2.5</td></tr></tbody></table><table-wrap-foot><fn><p><sup>*</sup>Incident changes in serostatus defined by crossing seropositivity cutoffs.</p><p><sup>&#8224;</sup>Incident changes in serostatus defined by a 4-fold increase or decrease in IgG levels (MFI-bg), with incident boosting episodes restricted to changes that ended above the seropositivity cutoff and incident waning episodes restricted to changes that started from above the seropositivity cutoff.</p></fn></table-wrap-foot></table-wrap>